WELCOME TO The Biotechnology REPORT
New Jersey Urology, LLC
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Virios Therapeutics, Inc. | January 05, 2022
Virios Therapeutics, Inc. a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced that Greg Duncan, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Conference, which is taking place virtually January 10 - 13, 2022.
The presentation will focus on the role of activated viruses triggering a wide range of conditions, includi...
Cyclica Inc. | February 10, 2022
Cyclica Inc. a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, launches Perturba Therapeutics Inc. a spin out from the Stagljar Lab at the University of Toronto, Donnelly Centre for Cellular and Biomolecular Research. Perturba is advancing a rich pipeline of assets from undrugged protein-protein interactions (PPIs).
Only a small subset of biologically important drug targets are currently being explored within the pharma industry. Per...
Alterity Therapeutics | June 03, 2022
Alterity Therapeutics (ASX: ATH,NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company's Phase 2 clinical trial of ATH434 for the treatment of patients with Multiple System Atrophy (MSA) is now open for enrolment in New Zealand.
MSA is a rare neurodegenerative disease. While it is similar to Parkinson's disease, MSA progresses m...
CELL AND GENE THERAPY
Ultima Genomics | June 09, 2022
Olink Holding AB (publ) ("Olink") (Nasdaq: OLK) and Ultima Genomics ("Ultima") today announced that they have entered into a collaboration to enable the use of the Olink® Explore high-throughput proteomics platform with Ultima's sequencing architecture.
Ultima Genomics and Olink are working towards a seamless pairing of the existing Olink® Explore assay and Ultima Genomics' sequencing system, and are collaborating with joint customers to enable ...
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE